On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
HOME > REGULATORY
REGULATORY
- Japan OKs FY2020 Budget, Record 35.86 Trillion Yen Allotted to Social Security
December 23, 2019
- Japan Approves Keytruda’s 1st Line RCC, Head and Neck Cancer Use, Bavencio’s Label Expansion and More
December 23, 2019
- MHLW Panel Concerned about Further Clinical Trial for Eisai’s Investigational Epilepsy Drug Following Death
December 23, 2019
- Japan to Shave Drug Spending by 4.38% in FY2020 Price Revision: MHLW
December 20, 2019
- Japan Panel Hammers Out FY2020 Drug Pricing Reform
December 20, 2019
- MHLW Council Holds Off Nonprescription Switches for Domperidone, Menatetrenone
December 20, 2019
- Councilor Mori, MHLW's Top Pharmacy Officer, to Bow Out at Year-End
December 19, 2019
- Japan, China, South Korea Adopt Joint Statement on Prevention and Control of Infectious Diseases
December 19, 2019
- FY2020 Drug Price Revision to Shed 110 Billion Yen in Central Govt Spending
December 18, 2019
- Promotion Guidelines Now in Full Effect, MHLW Starts Survey to Capture Leading Examples of Company Set-Ups
December 17, 2019
- Nobel Laureate Honjo Presses for More AMED Funding for Basic Research
December 17, 2019
- Up-to-5-Band Plan OK’ed for Unreasonable Generic Price Rises, Change to Affect Single Price Band Rule Too
December 16, 2019
- Chuikyo OKs Coverage for Risk-Reducing Breast and Ovary Removal in Cancer Patients
December 16, 2019
- PMDA Reviewing Safety Risks for Cosentyx, Suglat and More
December 16, 2019
- Chuikyo Members Oppose Creation of Medical Fees for “Formularies” at Special Function Hospitals
December 16, 2019
- Chuikyo Approves Coverage for Chugai’s FoundationOne as Companion Diagnostic for Lynparza
December 16, 2019
- Chuikyo Settles on “Third Price Revision” for Expansion of Comparator PMP Deduction Rule
December 16, 2019
- 6 Drugs Face Generic Entries, 2 Firms to Roll Out Symbicort Copies: December Listing
December 12, 2019
- Xolair Adds Pollen Allergy Use in Japan after 19-Day Delay
December 12, 2019
- Cosentyx, Lumicef Get Orphan Status for Add’l Indications
December 11, 2019
ページ
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan will trim the NHI price of Eli Lilly Japan’s Alzheimer’s treatment Kisunla (donanemab) by 3.93% under the cost-effectiveness assessment…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…